| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.0023 | 1 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0012 | 1 |